LifeStance Health Group (NASDAQ:LFST) Stock Dropped to Buy by Wall Street Zen

LifeStance Health Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded LifeStance Health Group from “strong buy” to “buy.” Analysts overall remain moderately bullish, with a consensus price target of $14.86.
  • LifeStance beat quarterly estimates, reporting EPS of $0.06 versus $0.04 expected and revenue of $455.86 million versus $431.59 million; revenue rose 25.3% year over year.
  • Insiders sold about 2.86 million shares worth $41.6 million during the quarter, including a sale of more than 2.2 million shares by insider Ryan Pardo.
  • MarketBeat previews the top five stocks to own by December 1st.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Sunday, Wall Street Zen reports.

A number of other research analysts have also recently commented on the company. BTIG Research raised their price target on LifeStance Health Group from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. Canaccord Genuity Group upped their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, November 6th. KeyCorp increased their price objective on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an "overweight" rating in a research note on Friday, November 6th. Weiss Ratings reiterated a "hold (c)" rating on shares of LifeStance Health Group in a research note on Wednesday, November 4th. Finally, Barclays raised their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an "overweight" rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.86.

Check Out Our Latest Research Report on LFST

LifeStance Health Group Stock Up 3.5%

NASDAQ LFST opened at $13.81 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.17. The company has a market cap of $5.25 billion, a price-to-earnings ratio of 72.69 and a beta of 1.35. The company has a 50 day moving average of $12.90 and a 200-day moving average of $9.84. LifeStance Health Group has a 1-year low of $6.09 and a 1-year high of $15.66.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The business had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The business's quarterly revenue was up 25.3% compared to the same quarter last year. On average, equities research analysts expect that LifeStance Health Group will post 0.20 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, CTO Vukasin Paunovich sold 42,067 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the completion of the sale, the chief technology officer directly owned 205,379 shares in the company, valued at $2,643,227.73. This represents a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ryan Pardo sold 2,216,585 shares of the firm's stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $14.58, for a total value of $32,317,809.30. Following the completion of the sale, the insider directly owned 334,935 shares in the company, valued at $4,883,352.30. This trade represents a 86.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,861,235 shares of company stock valued at $41,646,338. Corporate insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently made changes to their positions in LFST. KBC Group NV bought a new position in LifeStance Health Group in the 1st quarter valued at approximately $29,000. Advisors Asset Management Inc. acquired a new position in shares of LifeStance Health Group during the third quarter worth $34,000. IFP Advisors Inc increased its holdings in shares of LifeStance Health Group by 316.5% during the second quarter. IFP Advisors Inc now owns 3,694 shares of the company's stock worth $40,000 after buying an additional 2,807 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock worth $44,000 after buying an additional 5,404 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock valued at $59,000 after acquiring an additional 7,987 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance's clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.

See Also

Analyst Recommendations for LifeStance Health Group (NASDAQ:LFST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LifeStance Health Group Right Now?

Before you consider LifeStance Health Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.

While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines